Article
Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver…
Frontiers in cellular and infection microbiology · 2022 · H. Gao, Y. Jin, L. Li, Q. Luo, P. Shen, J. Su, Z. Wu, T. Xiao, Y. Xiao, X. Yu, B. Zheng, W. Zhou
Key facts
| Title | Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. |
|---|---|
| First author | H. Gao, Y. Jin, L. Li, Q. Luo, P. Shen, J. Su, Z. Wu, T. Xiao, Y. Xiao, X. Yu, B. Zheng, W. Zhou |
| Journal | Frontiers in cellular and infection microbiology |
| Published | Jan 18, 2022 |
| DOI | 10.3389/fcimb.2021.761192 |
| PubMed ID | 35118004 |
| PMC ID | PMC8804384 |
| Devices mentioned | 761192 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1